Cinclus Pharma Holding AB (publ) (STO:CINPHA)
Sweden flag Sweden · Delayed Price · Currency is SEK
16.08
+0.34 (2.16%)
At close: Jul 8, 2025

Cinclus Pharma Holding AB Company Description

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China.

The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease.

It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori (H.

pylori). Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.

Cinclus Pharma Holding AB (publ)
Country Sweden
Founded 2014
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 18
CEO Christer Ahlberg

Contact Details

Address:
Kungsbron 1
Stockholm, 11122
Sweden
Phone 46 8 13 33 10
Website cincluspharma.com

Stock Details

Ticker Symbol CINPHA
Exchange Nasdaq Stockholm
Fiscal Year January - December
Reporting Currency SEK
ISIN Number SE0020388577
SIC Code 2834

Key Executives

Name Position
Christer Ahlberg Chief Executive Officer and President
Dr. Lennart Hansson Ph.D. Co-founder and Chairman of the Board
Peter Unge Co-founder and Director
Maria Engstrom Chief Financial Officer
Jesper Wiklund Director of Corporate and Business Development
Kajsa Larsson Chief Medical Officer